Immunocore Hldgs Q2 2024 GAAP EPS $(0.23) Beats $(0.45) Estimate, Sales $75.400M Beat $74.580M Estimate
Portfolio Pulse from Benzinga Newsdesk
Immunocore Holdings (NASDAQ:IMCR) reported better-than-expected Q2 2024 results with a GAAP EPS of $(0.23), beating the estimate of $(0.45). Sales also surpassed expectations, reaching $75.4 million, a 24.21% increase from the same period last year.
August 08, 2024 | 11:25 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Immunocore Holdings (NASDAQ:IMCR) reported Q2 2024 GAAP EPS of $(0.23), beating the estimate of $(0.45). Sales were $75.4 million, surpassing the $74.58 million estimate and marking a 24.21% increase YoY.
The better-than-expected earnings and revenue growth indicate strong performance, likely boosting investor confidence and positively impacting the stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100